Not since the first successful polio vaccine in 1955 has the world awaited a vaccine with so much hope as it is doing for Covid-19. The virus, Sars-Cov2, and the candidate vaccines are charging ahead at a speed that’s unparalleled.  

As of 11 June, more than 7.25 million people were infected by the virus globally. And as per the World Health Organization’s (WHO) updated list of potential vaccines, there are 10 candidates in clinical development, 123 in preclinical evaluation. 

The race for a vaccine is intensifying; countries are betting not just financial but immense political capital on an antidote to the virus.


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Sign up to our India edition to read this story instantly

To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.

If you’ve already signed up, just enter your email below or login using Facebook or Google.